Aim:

To investigate the activity of RRR--tocopheryloxybutyric acid (TOB), an ether analog of RRR--tocopheryl succinate (VES), in prostate cancer cells.

Methods:

VES and TOB were used to treat prostate cancer LNCaP, PC3, and 22Rv1 cells and primary-cultured prostate fibroblasts. The proliferation rates were determined by MTT assay, the cell viabilities were determined by trypan blue exclusion assay, and the cell deaths were evaluated by using Cell Death Detection ELISA kit. The protein expression levels were determined by Western blot analysis.

Results:

The MTT growth assay demonstrated that TOB could effectively suppress the proliferation of prostate cancer cells, but not normal prostate fibroblasts. Mechanism dissections revealed that TOB reduced cell viability and induced apoptosis in prostate cancer cells similar to VES. In addition, both TOB and VES suppressed prostate-specific antigen (PSA) at the transcriptional level leading to reduced PSA protein expression. Furthermore, vitamin D receptor (VDR) expression increased after the addition of TOB.

Conclusion:

Our data suggests that the VES derivative, TOB, is effective in inhibiting prostate cancer cell proliferation, suggesting that TOB could be used for both chemopreventive and chemotherapeutic purposes in the future.

References

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106–30. | PubMed | ISI |
2. Chiu BC, Ji BT, Dai Q, Gridley G, McLaughlin JK, Gao YT, et al. Dietary factors and risk of colon cancer in Shanghai, China. Cancer Epidemiol Biomarkers Prev 2003; 3: 201–8.
3. Kristal AR, Stanford JL, Cohen JH, Wicklund K, Patterson RE. Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1999; 10: 887–92.
4. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029–35. | Article | PubMed | ISI |
5. Zhang Y, Ni J, Messing EM, Chang E, Yang CR, Yeh S. Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells. Proc Natl Acad Sci USA 2002; 99: 7408–13. | Article | PubMed | ChemPort |
6. Ni J, Chen M, Zhang Y, Li R, Huang J, Yeh S. Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery. Biochem Biophys Res Commun 2003; 300: 357–63. | Article | PubMed | ChemPort |
7. Zhang M, Altuwaijri S, Yeh S. RRR--tocopheryl E succinate inhibits human prostate cancer cell invasiveness. Oncogene 2004; 23: 3080–8. | Article | PubMed | ChemPort |
8. Israel K, Yu W, Sanders BG, Kline K. Vitamin E succinate induces apoptosis in human prostate cancer cells: role for Fas in vitamin E succinate-triggered apoptosis. Nutr Cancer 2000; 36: 90–100. | Article | PubMed | ISI | ChemPort |
9. Akazawa A, Nishikawa K, Suzuki K, Asano R, Kumadaki I, Satoh H, et al. Induction of apoptosis in a human breast cancer cell overexpressing ErbB-2 receptor by alpha-tocopheryloxybutyric acid. Int J Pharmacol 2002; 89: 417–21. | ChemPort |
10. Djuric Z, Heilbrun LK, Lababidi S, Everett-Bauer CK, Fariss MW. Growth inhibition of MCF-7 and MCF-10A human breast cells by alpha-tocopheryl hemisuccinate, cholesteryl hemisuccinate and their ether analogs. Cancer Lett 1997; 111: 133–9. | Article | PubMed | ChemPort |
11. Yano T, Yajima S, Hagiwara K, Kumadaki I, Yano Y, Otani S, et al. Vitamin E inhibits cell proliferation and the activation of extracellular signal-regulated kinase during the promotion phase of lung tumorigenesis irrespective of antioxidative effect. Car-cinogenesis 2000; 21: 2129–33. | ChemPort |
12. Fariss MW, Fortuna MB, Everett CK, Smith JD, Trent DF, Djuric Z. The selective antiproliferative effects of alpha-tocopheryl hemisuccinate and cholesteryl hemisuccinate on murine leukemia cells result from the action of the intact compounds. Cancer Res 1994; 54: 3346–51. | PubMed | ISI | ChemPort |
13. Ni J, Wen X, Yao J, Chang HC, Yin Y, Zhang M, et al. Toco-pherol-associated protein suppresses prostate cancer cell growth by inhibition of the phosphoinositide 3-kinase pathway. Cancer Res 2005; 65: 9807–16. | Article | PubMed | ChemPort |
14. Seamonds B, Yang N, Anderson K, Whitaker B, Shaw LM, Bollinger JR. Evaluation of prostate-specific antigen and pro-static acid phosphatase as prostate cancer markers. Urology 1986; 28: 472–9. | Article | PubMed | ChemPort |
15. Stewart LV, Weigel NL. Vitamin D and prostate cancer. Exp Biol Med (Maywood) 2004; 229: 277–84. | PubMed | ChemPort |
16. Zi X, Agarwal R. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc Natl Acad Sci USA 1999; 96: 7490–5. | Article | PubMed | ChemPort |
17. Beer TM, Hough KM, Garzotto M, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in advanced prostate cancer. Semin Oncol 2001; 28: 49–55. | Article | PubMed | ISI | ChemPort |
18. Lawson KA, Anderson K, Simmons-Menchaca M, Atkinson J, Sun L, Sanders BG, et al. Comparison of vitamin E derivatives alpha-TEA and VES in reduction of mouse mammary tumor burden and metastasis. Exp Biol Med (Maywood) 2004; 229: 954–63. | PubMed | ChemPort |
19. Wu Y, Zu K, Ni J, Yeh S, Kasi D, James NS, et al. Cellular and molecular effects of alpha tocopheryloxybutyrate: lessons for the design of vitamin E analog for cancer prevention. Anticancer Res 2004; 24: 3795–802. | PubMed | ChemPort |
20. Kasamon KM, Dawson NA. Update on hormone-refractory prostate cancer. Curr Opin Urol 2004; 14: 185–93. | Article | PubMed | ISI |